AHA Video: Ticagrelor may negate the need to assess genetic variations

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Click to play
AHA Video: Paul A. Gurbel, MD
Center for Thrombosis Research at Sinai Hospital
Baltimore, MD

CHICAGO--Paul A. Gurbel, MD, from the Center for Thrombosis Research at Sinai Hospital in Baltimore, who was the principal investigator of the ONSET/OFFSET and RESPOND studies, reviews findings from new genotyping analyses, which show genotype variations and metabolizer status does not affect platelet inhibition for patients taking ticagrelor (Brilinta, AstraZeneca).

Gurbel also speaks to how these outcomes could affect real-life clinical practice, if the antiplatelet agent is approved.